A multicenter, open-label, long-term safety extension of phase II studies ABE4869G and ABE4955G in patients with mild to moderate alzheimer�s disease
Read time: 1 mins
Last updated:12th Sep 2012
To assess the long-term safety and tolerability of crenezumab administered subcutaneously (SC) every 2 weeks (q2w) or intravenously (IV) every 4 weeks (q4w), in eligible patients with Alzheimer�s disease who participated in Study ABE4869g or ABE4955g and completed the Week 73 study visit, including brain MRI.
|Study start date||2012-09-12|